Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| Adjuvant Definitive TherapyNCT06990737 | University of California, DavisPHASE2 | WITHDRAWN Poor accrual | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-08-31 |
| CamlipixantNCT07684586 | GlaxoSmithKlinePHASE1 | WITHDRAWN The study has been withdrawn given the recent decision to cease further development of camlipixant in refractory chronic cough (RCC) based on Phase 3 program results. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-08-31 |
| ValsartanNCT06536309 | Brigham and Women's HospitalPHASE4 | WITHDRAWN Due to changes in HFpEF treatment landscape, no recruitment activities were initiated and no participants were enrolled. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-08-31 |
| Sacubitril-valsartanNCT06536309 | Brigham and Women's HospitalPHASE4 | WITHDRAWN Due to changes in HFpEF treatment landscape, no recruitment activities were initiated and no participants were enrolled. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-08-31 |
| PembrolizumabNCT07639242 | UNC Lineberger Comprehensive Cancer CenterPHASE2 | SUSPENDED Administrative | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-08-28 |
| OlomorasibNCT07639242 | UNC Lineberger Comprehensive Cancer CenterPHASE2 | SUSPENDED Administrative | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-08-28 |
| abataceptNCT07388563 | National Cancer Institute (NCI)PHASE1 | SUSPENDED New recruitment on hold for a protocol design amendment/modification. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-08-26 |
| azacitidineNCT07388563 | National Cancer Institute (NCI)PHASE1 | SUSPENDED New recruitment on hold for a protocol design amendment/modification. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-08-26 |
| VenetoclaxNCT06514261 | National Cancer Institute (NCI)PHASE1 | SUSPENDED Other - Pending amendment for study expansion. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-08-25 |
| IadademstatNCT06514261 | National Cancer Institute (NCI)PHASE1 | SUSPENDED Other - Pending amendment for study expansion. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-08-25 |
| AzacitidineNCT06514261 | National Cancer Institute (NCI)PHASE1 | SUSPENDED Other - Pending amendment for study expansion. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-08-25 |
| Trifluridine + TipiracilNCT07011550 | M.D. Anderson Cancer CenterPHASE2 | SUSPENDED PI Request | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-08-25 |
| BMS-986340NCT07011550 | M.D. Anderson Cancer CenterPHASE2 | SUSPENDED PI Request | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-08-25 |
| BevacizumabNCT07011550 | M.D. Anderson Cancer CenterPHASE2 | SUSPENDED PI Request | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-08-25 |
| NivolumabNCT07011550 | M.D. Anderson Cancer CenterPHASE2 | SUSPENDED PI Request | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-08-25 |
| Idarubicin versus daunorubicinNCT00363025 | Acute Leukemia French AssociationPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2008-02-21 |
| SAM-315NCT00474552 | Wyeth is now a wholly owned subsidiary of PfizerPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-02-18 |
| CisplatinNCT00322920 | University of Alabama at BirminghamPHASE1 | TERMINATED Low accrual | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-02-15 |
| TopotecanNCT00322920 | University of Alabama at BirminghamPHASE1 | TERMINATED Low accrual | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-02-15 |
| Genasense® (, oblimersen sodium G3139)NCT00517218 | Genta IncorporatedPHASE3 | WITHDRAWN Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2008-02-11 |
| azithromycinNCT00610623 | Anbics Management-Services AgPHASE2 | TERMINATED The sponsor decided to stop the study prematurely because of financial issues | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-02-08 |
| HyalganNCT00323778 | Hospital for Special Surgery, New YorkPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-02-06 |
| DuloxetineNCT00399022 | Sheba Medical CenterNA | WITHDRAWN Funding was not recieved | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-31 |
| IdazoxanNCT00294944 | Sheba Medical CenterPHASE3 | WITHDRAWN Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2008-01-29 |
| Viread (300 mg Tenofovir disoproxil fumarate) once dailyNCT00356616 | Germans Trias i Pujol HospitalPHASE4 | TERMINATED terminated | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2008-01-29 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |